AI Article Synopsis

  • Src kinases act as negative regulators of cell survival driven by platelet-derived growth factor (PDGF), impacting both development and disease.
  • The study identified PDGF receptor mutants lacking Src binding sites, showing that PDGF-stimulated cell survival relies on the PI3K pathway, which Src inhibits.
  • Src is involved in phosphorylating and regulating c-Cbl, an essential protein for PDGF receptor degradation, positioning Src kinases as potential therapeutic targets for diseases linked to cell survival and apoptosis.

Article Abstract

Regulation of growth factor dependent cell survival is crucial for development and disease progression. Here, we report a novel function of Src kinases as a negative regulator of platelet-derived growth factor (PDGF) dependent cell survival. We characterized a series of PDGF alpha receptor (PDGFRA) mutants, which lack the binding sites for Src, phosphatidylinositol 3'-kinase (PI3K), SHP-2 or phospholipase C-gamma. We found that PDGFRA-dependent cell survival was mainly mediated through activation of PI3K, and was negatively regulated by Src. Characterization of the downstream signaling events revealed that PI3K activates the protein kinase Akt, which in turn phosphorylates and thus inactivates proapoptotic Forkhead transcription factors. Src phosphorylates the ubiquitin-ligase c-Cbl, which is required for degradation of the activated receptor. Consequently, overexpression of c-Cbl prevented PDGFRA-mediated cell survival, whereas it did not affect this response, when Src was unable to associate with the receptor. This novel function of Src in antiapoptotic signaling introduces Src kinases as an interesting therapeutic target in apoptosis related diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.febslet.2006.11.034DOI Listing

Publication Analysis

Top Keywords

cell survival
16
antiapoptotic signaling
8
pdgf alpha
8
alpha receptor
8
negatively regulated
8
src
8
regulated src
8
growth factor
8
dependent cell
8
novel function
8

Similar Publications

Glioblastoma (GBM) is one of the most common primary malignant brain tumors. Annually, there are about six instances recorded per 100,000 inhabitants. Treatment for GB has not advanced all that much.

View Article and Find Full Text PDF

Objective: Searching for potential biomarkers and therapeutic targets for early diagnosis of gynecological tumors to improve patient survival.

Methods: Microarray datasets of cervical cancer (CC) and ovarian cancer (OC) were downloaded from the Gene Expression Omnibus (GEO) database, then, differential gene expression between cancerous and normal tissues in the datasets was analyzed. Weighted gene co-expression network analysis (WGCNA) was performed to screen for co-expression modules associated with CC and OC.

View Article and Find Full Text PDF

Background: Gliomas, particularly glioblastoma (GBM), are the most common and aggressive primary brain tumors in adults, characterized by high malignancy and frequent recurrence. Despite standard treatments, including surgery, radiotherapy, and chemotherapy, the prognosis for GBM remains poor, with a median survival of less than 15 months and a five-year survival rate below 10%. Tumor heterogeneity and resistance to treatment create significant challenges in controlling glioma progression.

View Article and Find Full Text PDF

Background: Low-grade glioma (LGG) is a slow-growing but invasive tumor that affects brain function. Histone deacetylases (HDACs) play a critical role in gene regulation and tumor progression. This study aims to develop a prognostic model based on HDAC-related genes to aid in risk stratification and predict therapeutic responses.

View Article and Find Full Text PDF

RASGEF1C as a novel prognostic biomarker for LUAD.

Discov Oncol

December 2024

Department of Thoracic Surgery, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New Area, Shanghai, China.

Lung adenocarcinoma (LUAD) is a common histologic lung cancer with high morbidity and mortality, and most patients have distant metastases at diagnosis. RasGEF Domain Family Member 1C (RASGEF1C) could regulated Alzheimer's disease. However, its function in various cancers, including LUAD, is poorly understood.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!